Profusa 2025 Q3 Earnings Net Loss Surges 788.7% Despite Debt Reduction

Profusa (PFSA) reported Q3 2025 results on Nov 19, 2025, with revenue plummeting to $0 from $75,000 in Q3 2024. The company narrowed losses to $0.70 per share (45.7% improvement) but recorded a $22.19 million net loss, up 788.7% year-over-year. No guidance adjustments were provided.

Revenue

The total revenue of Profusa decreased by 100.0% to $0 in 2025 Q3, down from $75,000 in 2024 Q3.

Earnings/Net Income

Profusa narrowed losses to $0.70 per share in 2025 Q3 from a loss of $1.29 per share in 2024 Q3 (45.7% improvement). Meanwhile, the company's net loss widened to $-22.19 million in 2025 Q3, representing a 788.7% increase from the $-2.50 million loss recorded in 2024 Q3. Despite a 45.7% improvement in EPS, the net loss surged 788.7%, indicating operational challenges.

Price Action

The stock price of Profusa has dropped 6.11% during the latest trading day, has plummeted 16.75% during the most recent full trading week, and has plummeted 47.50% month-to-date.

Post-Earnings Price Action Review

The strategy of buying Profusa (PFSA) shares on the date of release of its quarterly financial reports and holding for 30 days resulted in a significant loss. The 3-year backtest shows a total of 9 quarters where the revenue equal q/q was reported. For 7 of those quarters, the stock price decreased in the following 30 days. The average maximum loss was 15.5% with a total loss of 105.5% cumulatively over the 7 quarters.

CEO Commentary

No direct quotes from the CEO were provided in the earnings report.

Guidance

The company outlined plans to commercialize Lumee™ Oxygen in the EU by early Q2 2026 and emphasized continued investment in digital treasury assets.

Additional News

Profusa completed a merger with NorthView Acquisition Corporation, reducing net debt to $14 million. The company raised $12 million via a convertible PIPE note and $7 million through an Equity Line of Credit, with $93 million remaining available. It also repaid $47 million of debt post-merger and plans to expand European sales for Lumee™ Oxygen, targeting 35% population coverage.